Literature DB >> 12107207

Cardiovascular consequences of early-onset growth hormone excess.

Annamaria Colao1, Letizia Spinelli, Alberto Cuocolo, Stefano Spiezia, Rosario Pivonello, Carolina di Somma, Domenico Bonaduce, Marco Salvatore, Gaetano Lombardi.   

Abstract

Acromegaly has relevant effects on the cardiovascular system, but few data deal with the early effects of GH and IGF-I excess. To study the early stage of acromegalic cardiomyopathy and give indirect evidence of the mechanisms underlying GH and IGF-I action on the human heart, 25 patients with uncomplicated acromegaly [15 young subjects with short-term (< or =5 yr) disease and 10 with long-term (>5 yr) disease] and 25 sex- and age-matched controls were studied. Cardiovascular risk parameters were studied by standard methods; cardiac morphology by M-mode and Doppler echocardiography, cardiac function at rest and at peak exercise by equilibrium radionuclide angiography, and vascular disease at common carotid arteries by Doppler ultrasonography. In the patient group these measurements were repeated after 6 months of treatment with octreotide-LAR (20-40 mg, im, every 28 d). Glucose, glycosylated hemoglobin, insulin, low density lipoprotein cholesterol, triglycerides, and fibrinogen levels were higher, and high density lipoprotein cholesterol levels were lower in acromegalic patients than in controls. Resting blood pressure was similar in patients and controls, whereas heart rate at rest and systolic blood pressure at peak exercise were higher in the patients. The left ventricular mass index was higher in acromegalic patients than in controls (123.3 +/- 8.9 vs. 81.5 +/- 4.3 g/m(2); P < 0.001); seven patients had left ventricular hypertrophy. Diastolic function was similar in the two groups. The ejection fraction at rest, but not at peak exercise, was significantly increased in the patients compared with controls. As a consequence the exercise-induced changes in the ejection fraction were lower in patients than controls (8.7 +/- 1.1% vs. 21.9 +/- 3.5%; P < 0.001). At common carotid ultrasonography, young patients with acromegaly had increased diastolic peak velocity and increased intima media thickness, even if neither patient nor controls had atherosclerotic plaques. Six months after OCT-LAR treatment, GH and IGF-I levels remarkably decreased in all patients; 8 (53.3%) achieved disease control. Insulin, total cholesterol, and fibrinogen levels reduced, whereas high density lipoprotein cholesterol levels increased. Both at rest and at peak exercise, heart rate significantly decreased, whereas systolic and diastolic blood pressures did not change. The left ventricular mass index was significantly reduced, but it was still higher than the control value (101.6 +/- 3.5 g/m(2); P < 0.01). The left ventricular ejection fraction at rest was significantly reduced, but its response at peak exercise was increased (16.3 +/- 2.4%), becoming similar to the control value. At common carotids, the intima media thickness of right and left arteries was significantly reduced as was the diastolic peak velocity without any change in systolic peak velocity. Short-term GH excess, despite causing enhanced cardiac performance at rest, reduces cardiac performance on effort and impairs vascular morphology. These deleterious effects of early-onset acromegaly are ameliorated by suppressing GH/IGF-I levels for 6 months.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107207     DOI: 10.1210/jcem.87.7.8573

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

Review 2.  Somatostatin agonists for treatment of acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Mol Cell Endocrinol       Date:  2007-11-29       Impact factor: 4.102

Review 3.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 4.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

5.  Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.

Authors:  Marianna Yaron; Elena Izkhakov; Jessica Sack; Ibrahim Azzam; Etty Osher; Karen Tordjman; Naftali Stern; Yona Greenman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

Review 6.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

7.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.

Authors:  A Colao; S Spiezia; C Di Somma; R Pivonello; P Marzullo; F Rota; T Musella; R S Auriemma; M C De Martino; G Lombardi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 9.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.

Authors:  Brian J Potter; Catherine Beauregard; Omar Serri
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.